TCV 116

Known as: TCV-116 
 

Topic mentions per year

Topic mentions per year

1992-2014
0102019922014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Aims/hypothesis. The results of the EUCLID trial (EURODIAB Controlled Trial of Lisinopril in Insulin-dependent Diabetes Mellitus… (More)
Is this relevant?
1999
1999
BACKGROUND Inhibition of the renin-angiotensin system by both angiotensin II type 1 receptor antagonists (AT1As) and angiotensin… (More)
Is this relevant?
1997
1997
The effects of chronic treatment with an angiotensin II receptor antagonist, candesartan cilexetil (TCV-116, 0.1, 1, 10 mg/kg… (More)
Is this relevant?
1997
1997
The renal protective properties of candesartan cilexetil (TCV-116), an angiotensin II type 1 receptor antagonist (AT1A), and… (More)
Is this relevant?
1997
1997
Unilateral ureteral obstruction (UUO) is a well established disease model leading to fibrosis of the obstructed kidney. In this… (More)
Is this relevant?
1995
1995
The purpose of this study was to assess the inhibitory effect of TCV-116, an orally active angiotensin II (Ang II) antagonist, on… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
BACKGROUND Previous studies have demonstrated that angiotensin II (Ang II) acts as a growth-promoting factor directly on cardiac… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1994
1994
We investigated the protective effect of angiotensin II (Ang II) type 1 receptor antagonist on myocardial ischemia-reperfusion… (More)
Is this relevant?
1994
1994
OBJECTIVE The objective of this study was to determine the renal protective effects of TCV 116, a novel, non-competitive… (More)
Is this relevant?
1994
1994
We examined whether specific blockade of the renin-angiotensin system is beneficial for the treatment of cardiac dysfunction in… (More)
Is this relevant?